Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer. (ctDNA_EOC)
Status
Conditions
Treatments
Details and patient eligibility
About
Epithelial ovarian cancer constitutes one of the most common gynecological malignancies.Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage.ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA.This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.
Full description
Epithelial ovarian cancer constitutes one of the most common gynecological malignancies, with an incidence rate of 3-12/100 000 woman per year. Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage. Liquid biopsy, which is meant to detect cancers by sequencing the DNA in a few drops of a person's blood. It may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation.
ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA. There is evidence that some of the ctDNA originates from tumor tissue. This, and the fact that ctDNA can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer.
This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- people aged 18years to 80years;
- Diagnosis of ovarian cancer is confirmed by two Pathologists independently;
- Pregnancy tests are negative.
Exclusion criteria
- With other type of malignancies;
- someone who refuse to participate the study.
Trial design
43 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal